Bio-Path Holdings to Present Data at 2024 European Hematology Association Congress

Core Insights - Bio-Path Holdings, Inc. is set to present interim results from its Phase 2 study of prexigebersen (BP1001) for acute myeloid leukemia (AML) at the 2024 European Hematology Association Congress [1][2][3] Company Overview - Bio-Path Holdings, Inc. is a biotechnology company focused on developing targeted nucleic acid cancer drugs using its proprietary DNAbilize® liposomal delivery and antisense technology [1][4] - The lead product candidate, prexigebersen (BP1001), targets the Grb2 protein and is currently in a Phase 2 study for blood cancers [4] - The company is also developing BP1002, which targets the Bcl-2 protein, and BP1003, a novel liposome-incorporated STAT3 antisense oligodeoxynucleotide [4] Clinical Study Insights - The interim results presented by Dr. Jorge Cortes indicate that prexigebersen is well-tolerated and shows compelling efficacy in newly diagnosed and refractory/relapsed AML patients, outperforming frontline therapy [2][3] - The poster presentation is scheduled for June 14, 2024, at 6:00 PM CEST, at IFEMA Madrid Recinto Ferial, Hall 7, with the abstract number P536 [3]